| 前收市價 | 36.93 |
| 開市 | 37.12 |
| 買盤 | 37.65 x 200 |
| 賣出價 | 38.00 x 100 |
| 今日波幅 | 37.03 - 38.08 |
| 52 週波幅 | 20.83 - 40.95 |
| 成交量 | |
| 平均成交量 | 418,859 |
| 市值 | 1.238B |
| Beta 值 (5 年，每月) | 1.04 |
| 市盈率 (最近 12 個月) | 29.35 |
| 每股盈利 (最近 12 個月) | 1.29 |
| 業績公佈日 | 2024年5月09日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 40.00 |
ZacksCollegium (COLL) to Report Q1 Earnings: Here's What to Expect
Collegium's (COLL) top line is likely to have been fueled by growth in the sales of pain drugs, Belbuca and Xtampza ER, in the first quarter of 2024.
ZacksCollegium Pharmaceutical (COLL) Stock Sinks As Market Gains: What You Should Know
Collegium Pharmaceutical (COLL) closed at $38.79 in the latest trading session, marking a -1.6% move from the prior day.
ZacksAre Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
